Media headlines about Natera (NASDAQ:NTRA) have been trending somewhat positive recently, Accern reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Natera earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 46.5743083144504 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news headlines that may have effected Accern’s scoring:

NTRA has been the topic of a number of analyst reports. ValuEngine cut Natera from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Zacks Investment Research cut Natera from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. BidaskClub cut Natera from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Morgan Stanley cut their target price on Natera from $18.00 to $13.00 and set an “overweight” rating on the stock in a research note on Monday, August 7th. Finally, Canaccord Genuity upped their target price on Natera from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, May 10th. Four equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $14.45.

Natera (NTRA) traded up 5.04% on Friday, hitting $10.62. The stock had a trading volume of 278,269 shares. Natera has a 12 month low of $7.35 and a 12 month high of $12.95. The stock’s market cap is $565.23 million. The firm’s 50 day moving average price is $9.97 and its 200-day moving average price is $9.55.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, August 8th. The medical research company reported ($0.52) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.52). Natera had a negative net margin of 62.64% and a negative return on equity of 137.46%. The firm had revenue of $53.60 million during the quarter, compared to the consensus estimate of $50.57 million. During the same quarter last year, the firm earned ($0.46) EPS. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. On average, analysts forecast that Natera will post ($2.08) EPS for the current year.

WARNING: This article was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at

Natera Company Profile

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with's FREE daily email newsletter.